F-box and leucine rich repeat protein 2Genealiases: FBL2 · FBL3
Q-omics provides the consensus-scored FBXL2 profile across patient tissues and cancer cell-line models. FBXL2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, FBXL2 is differentially expressed in 15, with the highest sampling consensus in THCA. Additionally, FBXL2 RNA expression shows 20,596 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight STAD, THCA, and UVM as cancer lineages where FBXL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXL2 survival associations across molecular data types. FBXL2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXL2 RNA expression–survival associations across cancer types. High FBXL2 expression shows unfavorable associations in STAD, LUSC, COAD, CESC and BLCA, but favorable associations in KIRP. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .009). Together, the overview and detailed table identify STAD as the clearest survival context for FBXL2 RNA expression.
This table summarizes FBXL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FBXL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXL2 shows lower tumor expression in THCA, KIRC, LUSC and KICH and higher tumor expression in HNSC and LIHC. The THCA box plot shows higher FBXL2 RNA expression in normal versus tumor tissue (log2 FC = −0.995, t-test p < 0.001).
This table shows molecular features associated with FBXL2 in patient tissues and cancer cell lines. In patient samples, FBXL2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
